LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,730 | -16.3% | 40,449 | 0.0% | 0.00% | – |
Q2 2023 | $57,033 | -6.0% | 40,449 | 0.0% | 0.00% | – |
Q1 2023 | $60,674 | +108246.4% | 40,449 | -16.5% | 0.00% | – |
Q4 2022 | $56 | -99.9% | 48,464 | 0.0% | 0.00% | – |
Q3 2022 | $55,000 | -46.6% | 48,464 | -25.6% | 0.00% | – |
Q2 2022 | $103,000 | -48.0% | 65,155 | -49.4% | 0.00% | – |
Q1 2022 | $198,000 | -37.1% | 128,683 | 0.0% | 0.00% | – |
Q4 2021 | $315,000 | -2.8% | 128,683 | 0.0% | 0.00% | – |
Q3 2021 | $324,000 | -11.7% | 128,683 | 0.0% | 0.00% | – |
Q2 2021 | $367,000 | +21.5% | 128,683 | 0.0% | 0.00% | – |
Q1 2021 | $302,000 | +37.9% | 128,683 | +3.5% | 0.00% | – |
Q4 2020 | $219,000 | +88.8% | 124,360 | 0.0% | 0.00% | – |
Q3 2020 | $116,000 | -8.7% | 124,360 | -14.9% | 0.00% | – |
Q2 2020 | $127,000 | +1.6% | 146,088 | -3.6% | 0.00% | – |
Q1 2020 | $125,000 | -7.4% | 151,487 | 0.0% | 0.00% | – |
Q4 2019 | $135,000 | -11.2% | 151,487 | -2.2% | 0.00% | – |
Q3 2019 | $152,000 | – | 154,850 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,005,379 | $83,313,000 | 5.12% |
Defender Capital, LLC. | 4,997,870 | $12,245,000 | 3.92% |
Raffles Associates | 543,590 | $1,332,000 | 1.28% |
Prescott General Partners LLC | 1,851,851 | $4,537,000 | 0.16% |
DCF Advisers, LLC | 85,000 | $208,000 | 0.08% |
Long Focus Capital Management, LLC | 215,000 | $527,000 | 0.07% |
Beirne Wealth Consulting Services, LLC | 45,000 | $110,000 | 0.06% |
DAFNA Capital Management LLC | 80,000 | $196,000 | 0.05% |
Strategic Wealth Investment Group, LLC | 65,069 | $159,000 | 0.04% |
Fort Sheridan Advisors LLC | 52,931 | $130,000 | 0.04% |